The prognosis of the patients from which the ESCC cell lines with high EMX2 expression had been established was significantly worse than that of other patients from which the ESCC cell lines with nil/minimal EMX2 expression had been established, both in terms of disease-specific survival (Figure 6A,C, DSS, p = 0.0207 and 0.0190 for all 20 patients and 16 patients with radical surgery, respectively), progression-free survival (Figure 6B, PFS, p = 0.0075 for all 20 patients), and disease-free survival (Figure 6D, DFS, p = 0.0122 for 16 patients with radical surgery). This evidence concerns the gene EMX2 and esophageal squamous cell carcinoma.